Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Autoimmune encephalitis (AE) management lacks standardized evidence-based guidelines.
• Existing research often focuses on specific antibody syndromes, neglecting broader AE categories.
• Expert consensus is crucial for guiding clinical practice in complex neurological conditions.

Purpose of the Study:

• To evaluate existing evidence for autoimmune encephalitis management steps.
• To provide expert consensus and recommendations where evidence is insufficient.
• To approach autoimmune encephalitis as a broad category, not limited to specific antibody syndromes.

Main Methods:

• Literature review by core authors from the Autoimmune Encephalitis Alliance Clinicians Network.
• Development of a draft based on reviewed literature.
• Electronic survey distributed to network members for expert opinion on controversial or evidence-lacking areas, with responses from 68 clinicians across 17 countries.

Main Results:

• Oral prednisone taper was the most favored bridging therapy (38%).
• Rituximab was the preferred maintenance therapy (46%).
• Maintenance immunosuppression is recommended by most responders after a second relapse in neuronal surface antibody (70%) or seronegative AE (61%) cases.
• Extended cancer screening (4 years) is favored for neuronal surface antibody (49%) or limbic encephalitis (46%) patients.

Conclusions:

• The study provides expert-driven recommendations for autoimmune encephalitis management, addressing therapy and monitoring.
• Consensus highlights the utility of specific immunosuppressive agents and screening protocols.
• Findings aim to standardize care for patients with autoimmune encephalitis, irrespective of specific antibody profiles.